PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
25 sept. 2024 08h30 HE
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
24 sept. 2024 08h00 HE
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Antibody Drug Conjugates Market Is Expected To Reach Revenue Of USD 51.2 Bn By 2033, at 15.8% CAGR: Dimension Market Research
05 sept. 2024 11h45 HE
|
Dimension Market Research
New York, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Overview The Global Antibody Drug Conjugates (ADCs) Market is projected to grow from USD 13.7 billion in 2024 to USD 51.2 billion by 2033, at a CAGR...
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
05 sept. 2024 09h00 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals, a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients...
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
04 sept. 2024 16h15 HE
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Radiance BioPharma sponsoring Investor Cruise Event 2024
29 août 2024 15h30 HE
|
Radiance BioPharma
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced...
iOmx Therapeutics Initiates Phase Ib with OMX-0407
22 août 2024 04h00 HE
|
iOmx Therapeutics AG
Data from the successful Phase Ia dose escalation study showed that OMX-0407 monotherapy demonstrated a favorable safety profile and signs of anti-tumor activity, with one durable complete response in...
Brachytherapy Devices Market Poised to Grow to US$ 1.9 Bn by 2034, With a 5.9% CAGR: Exclusive Report by Transparency Market Research, Inc.
15 août 2024 06h45 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Aug. 15, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global brachytherapy...
Groundbreaking Voice of the Patient Report for pediatric low-grade glioma (pLGG) published by Pediatric Brain Tumor Foundation
07 août 2024 09h30 HE
|
Pediatric Brain Tumor Foundation
Report documents the experiences of pLGG patients, survivors, their families, to inform future drug development for most common brain tumor type in kids
ICPO Foundation kooperiert mit dem American Hospital Dubai, um ein ICPO Collaborating Center im Nahen Osten zu etablieren.
11 juil. 2024 00h00 HE
|
ICPO Foundation
Diese Kooperation stärkt die globalen Bildungsstandards für Radiotheranostics und wird den Patientenzugang zu einer neuen Generation effektiver Krebstherapien in den Vereinigten Arabischen Emiraten...